Docusign (NASDAQ:DOCU) Now Covered by Analysts at FBN Securities

Share on StockTwits

FBN Securities started coverage on shares of Docusign (NASDAQ:DOCU) in a research note released on Tuesday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $60.00 target price on the stock.

A number of other equities analysts also recently issued reports on DOCU. William Blair reissued an outperform rating on shares of Vail Resorts in a report on Friday, June 7th. Piper Jaffray Companies dropped their price objective on shares of Zafgen from $18.00 to $6.00 and set a hold rating on the stock in a report on Monday, March 11th. Wedbush set a $17.00 price objective on shares of Zumiez and gave the stock a sell rating in a report on Friday, June 7th. Finally, ValuEngine raised shares of Zogenix from a buy rating to a strong-buy rating in a report on Thursday, June 27th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $61.36.

Shares of DOCU stock opened at $53.20 on Tuesday. The business has a 50 day moving average of $51.95. Docusign has a 52 week low of $35.06 and a 52 week high of $68.35. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.76 and a quick ratio of 1.76.

Docusign (NASDAQ:DOCU) last posted its quarterly earnings data on Thursday, June 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.30. The company had revenue of $213.96 million for the quarter, compared to the consensus estimate of $208.15 million. Docusign had a negative net margin of 26.54% and a negative return on equity of 22.27%. The firm’s revenue was up 37.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.01 earnings per share. Equities research analysts anticipate that Docusign will post -0.99 EPS for the current fiscal year.

In other Docusign news, COO Scott V. Olrich sold 10,000 shares of Docusign stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $53.39, for a total transaction of $533,900.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CRO Loren Alhadeff sold 11,579 shares of Docusign stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $53.12, for a total transaction of $615,076.48. The disclosure for this sale can be found here. Insiders have sold 600,988 shares of company stock worth $31,067,181 in the last ninety days. Insiders own 13.60% of the company’s stock.

Large investors have recently modified their holdings of the business. Sonora Investment Management LLC bought a new stake in shares of Docusign during the first quarter valued at approximately $31,000. Clean Yield Group bought a new stake in shares of Docusign during the first quarter valued at approximately $31,000. Legacy Advisors LLC bought a new stake in shares of Docusign during the first quarter valued at approximately $38,000. Rehmann Capital Advisory Group raised its position in shares of Docusign by 226.1% during the first quarter. Rehmann Capital Advisory Group now owns 874 shares of the company’s stock valued at $45,000 after buying an additional 606 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. bought a new stake in Docusign in the first quarter worth $66,000. 61.15% of the stock is currently owned by institutional investors and hedge funds.

Docusign Company Profile

DocuSign, Inc provides cloud based software in the United States. The company offers e-signature solution that enables businesses to digitally prepare, execute, and act on agreements. The company sells its products through direct, partner-assisted, and Web-based sales. It serves enterprise businesses, commercial businesses, and small businesses, such as professionals, sole proprietorships and individuals.

Recommended Story: Strangles

Analyst Recommendations for Docusign (NASDAQ:DOCU)

Receive News & Ratings for Docusign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Docusign and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.